

Atty Lxt 8325-16 M4-US1 PATENT SENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washing

5/9/02 Signature

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

WANG and PABO

Serial No.: 09/636,243

Filing Date: August 10, 2000

Title: DIMERIZING PEPTIDES

Group Art Unit: 1627

Examiner: Bhatti, Tahira H.

TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed April 9, 2002, enclosed are the following:

- a copy of the Notice to Comply with Requirements for Patent Applications
 Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
 - a Statement to Support Filing and Submission In Accordance With 37
 C.F.R. §§ 1.821-1.825; and
 - 3) a Sequence Listing in paper form and computer readable form.

Atty Dkt 8325-1004 M4-US1 USSN: 09/636,243 PATENT

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: May 9, 2002

Dahna S. Pasternak Registration No. 41,411

ROBINS & PASTERNAK LLP 545 Middlefield Road, Suite 180 Menlo Park, CA 94025 Telephone: (650) 325-7812

Facsimile: (650) 325-7823



UNITED STATES PATENT AND TRADEM REGGES VED

APR 15 2002

FIRST NAROBINS & PASTERNAK ATIPRNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. FILING DATE Bryan S. Wang 08/10/2000 6438 09/636,243

04/09/2002

11

7590

ROBINS & PASTERNAK LLP 545 MIDDLEFIELD ROAD SUITE 180 MENLO PARK, CA 94025



EXAMINER BHATTI, TAHIRA H PAPER NUMBER ART UNIT

1627 DATE MAILED: 04/09/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

UNITED ST. EXEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/636,243	8/10/02		



EXA	AMINER
Tahira Bhatti	
ART UNIT	PAPER NUMBER
1627	11
DATE MAILED:	

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amin Acid Sequence Disclosures.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed to Tahira Bhatti whose telephone number is (703) 605-1203. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

Tahira Bhatti Patent Examiner Technology center 1600 Art Unit 1627 April 5th. 2002

BENNETT CELSA

Application N .:09/636,243

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

·
 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
 The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: .
licant Must Provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
questions regarding compliance to these requirements, please contact:
Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 entln Software Program Support (SIRA)
Technical Assistance703-287-0200 To Purchase Patentln Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



Atty Dkt 8325-1004 M4-US1 PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington,

D.C. 20231 on <u>O9-MAY-2022</u>

Date

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

WANG and PABO

Serial No.: 09/636,243

Filing Date: August 10, 2000

Title: DIMERIZING PEPTIDES

Group Art Unit: 1627

Examiner: Bhatti, Tahira H.

RECEIVED
MAY 2 0 2002

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned hereby states that the content of the attached papers and the computer-readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Registration No. 41,411

Date

May 9, 2002

Dahna S. Pasternak

ROBINS & PASTERNAK LLP 545 Middlefield Road, Suite 180

Menlo Park, CA 94025 Telephone: (650) 325-7812

Fax: (650) 325-7823